Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections
- 876 Downloads
The potential of aerosol phage therapy for treating lung infections has been demonstrated in animal models and clinical studies. This work compared the performance of two dry powder formation techniques, spray freeze drying (SFD) and spray drying (SD), in producing inhalable phage powders.
A Pseudomonas podoviridae phage, PEV2, was incorporated into multi-component formulation systems consisting of trehalose, mannitol and L-leucine (F1 = 60:20:20 and F2 = 40:40:20). The phage titer loss after the SFD and SD processes and in vitro aerosol performance of the produced powders were assessed.
A significant titer loss (~2 log) was noted for droplet generation using an ultrasonic nozzle employed in the SFD method, but the conventional two-fluid nozzle used in the SD method was less destructive for the phage (~0.75 log loss). The phage were more vulnerable during the evaporative drying process (~0.75 log further loss) compared with the freeze drying step, which caused negligible phage loss. In vitro aerosol performance showed that the SFD powders (~80% phage recovery) provided better phage protection than the SD powders (~20% phage recovery) during the aerosolization process. Despite this, higher total lung doses were obtained for the SD formulations (SD-F1 = 13.1 ± 1.7 × 104 pfu and SD-F2 = 11.0 ± 1.4 × 104 pfu) than from their counterpart SFD formulations (SFD-F1 = 8.3 ± 1.8 × 104 pfu and SFD-F2 = 2.1 ± 0.3 × 104 pfu).
Overall, the SD method caused less phage reduction during the powder formation process and the resulted powders achieved better aerosol performance for PEV2.
KEY WORDSaerosols antibiotic-resistant bacteria phage therapy pulmonary infections
Colony formation unit
Differential scanning calorimetry
Dynamic vapor sorption
Fine particle fraction
High performance liquid chromatography
Multi-stage liquid impinger
Plaque formation unit
Scanning electron microscope
Spray freeze drying
Glass transition temperature
ACKNOWLEDGMENTS AND DISCLOSURES
This work was financially supported by the Australian Research Council (Discovery Project DP150103953). Authors are grateful to Tony Smithyman of Special Phage Services for his valuable discussion and advice. Sharon Leung is a research fellow supported by the University of Sydney. Thaigarajan Parumasivam is a recipient of the Malaysian Government Scholarship. H-KC is funded by the National Institutes of Health (NIH Project no.1R21AI121627-01).
- 2.In: Foundation TAL, editor. The Australian Lung Foundation’s case statement: respiratory infectious disease burden in Australia. 2007.Google Scholar
- 6.Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, et al. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc. 2014;11(7):1120–9.CrossRefPubMedGoogle Scholar
- 14.Essoh C, Blouin Y, Loukou G, Cablanmian A, Lathro S, Kutter E, et al. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. Plos One. 2013;8(4).Google Scholar
- 15.Larche J, Pouillot F, Essoh C, Libisch B, Straut M, Lee JC, et al. Rapid identification of international multidrug-resistant Pseudomonas aeruginosa clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophages. Antimicrob Agents Chemother. 2012;56(12):6175–80.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy, in Clin Otolaryngol. 2009;349–357.Google Scholar
- 21.Kutter E, Borysowski J, Miedzybrodzki R, Gorski A, Weber-Dabrowska B, Kutateladze M, et al. Clinical phage therapy. In: Borysowski J, Miedzybrodzki R, Gorski A, editors. Therapy: current research and applications. Caister Academic Press; 2014. p. 257–88.Google Scholar
- 24.Semler DD, Lyunch KH, Dennis JJ. The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections. Frontiers in cellular and infection microbiology, 2012. 1. UNSP 27.Google Scholar
- 28.Sahota JS, Smith CM, Radhakrishnan P, Winstanley C, Goderdzishvili M, Chanishvili N, et al. Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J Aerosol Med Pulm Drug Deliv. 2015;28(5):353–60.CrossRefPubMedGoogle Scholar
- 33.Merabishvili M, Vervaet C, Pirnay J-P, De Vos D, Verbeken G, Mast J, et al. Stability of Staphylococcus aureus phage ISP after freeze-drying (Lyophilization). Plos One. 2013;8(7).Google Scholar
- 34.Ackermann HW, Tremblay D, Moineau S. Long-term bacteriophage preservation. World Fed Cult Collect Newsl. 2004;38:35–40.Google Scholar
- 38.Carlson K. Appendix. Working with bacteriophages: common techniques and methodological approaches. In: Kutter E, and Sulakvelidze A, editors. Bacteriophages: biology and applications. Boca Raton: CRC Press; 2005. p. 437–94.Google Scholar
- 42.Leuenberger H. Process of drying a particulate material and apparatus for implementing the process. 1987. US patent 4,608,764.Google Scholar
- 58.Curtright AJ, Abedon ST. Phage therapy: emergent property pharmacology. J Bioanal Biomed. 2011; S6, article 002.Google Scholar